Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer was written by Wong, Vanessa;de Boer, Richard;Baron-Hay, Sally;Blum, Robert;Boyle, Frances;Chua, Susan;Clarke, Kerrie;Cuff, Katharine;Green, Michael;Lim, Elgene;Mok, Kelly;Nott, Louise;Nottage, Michelle;Tafreshi, Ali;Tsoi, Daphne;Uccellini, Anthony;Hong, Wei;Gibbs, Peter;Lok, Sheau Wen. And the article was included in Clinical Breast Cancer.Electric Literature of C23H30N8O This article mentions the following:
International guidelines recommend combining a CDK4/6 inhibitor and endocrine therapy (ET) as first line treatment for hormone receptor (HR) pos., HER2 neg. metastatic breast cancer (MBC). Results from MONALEESA-2 demonstrate superior progression free survival (PFS) and overall survival (OS) with ribociclib (CDK4/6 inhibitor) and ET compared to ET alone. Real world outcomes have yet to be reported.KARMA is a non-interventional registry of Australian patients receiving first-line treatment with ribociclib and aromatase inhibitor (AI), obtained via a Medicine Access Program (MAP) for HR+, HER2- MBC. Outcomes were compared with the ribociclib/letrozole cohort in MONALEESA-2.Data from 160 patients at 17 sites was analyzed. Median follow-up is 36.5 mo. Compared to MONALEESA-2, patients were numerically younger (54.3 vs. 62 years), with higher rates of bone-only metastases (31% vs. 21%). A total of 63 of 160 (39%) patients remain on treatment. A total of 56% of patients had at least 1 dose reduction, with neutropenia (68%) and abnormal liver enzymes (17%) the most common reasons. A total of 17 of 160 (11%) discontinued treatment due to toxicity, with no treatment related deaths. Median PFS was not reached (95% CI 29.9- NR), with PFS at 12 mo and 18 mo being 76% and 67% resp. vs. 25.3 mo, 73% and 63% in MONALEESA-2.The ribociclib and AI combination was well tolerated in this real-world setting. The KARMA registry cohort achieved a superior PFS (>36.5 mo) to MONALEESA-2, potentially due to more favorable baseline disease characteristics. Less frequent assessment scheduling in this non trial setting may also contribute. In the experiment, the researchers used many compounds, for example, 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (cas: 1211441-98-3Electric Literature of C23H30N8O).
7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (cas: 1211441-98-3) belongs to piperazine derivatives. Industrial applications of piperazine include the manufacture of plastics, resins, pesticides and brake fluids. Although many piperazine derivatives occur naturally, piperazine itself can be synthesized by reacting alcoholic ammonia with 1,2-dichloroethane, by the action of sodium and ethylene glycol on ethylene diamine hydrochloride, or by reduction of pyrazine with sodium in ethanol.Electric Literature of C23H30N8O
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics